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Abstract: Methyl-CpG binding protein 2 (MeCP2) is a multifunctional epigenetic reader playing a role
in transcriptional regulation and chromatin structure, which was linked to Rett syndrome in humans.
Here, we focus on its isoforms and functional domains, interactions, modifications and mutations
found in Rett patients. Finally, we address how these properties regulate and mediate the ability of
MeCP2 to orchestrate chromatin compartmentalization and higher order genome architecture.
Keywords: DNA modifications; DNA methylation readers; higher order chromatin structure;
heterochromatin; MeCP2; Rett syndrome
1. Introduction
In humans, the two meter long genomic DNA is hierarchically folded to fit inside the
membrane-bound micrometer-scale cell nucleus. Individual chromosomes occupy distinct subnuclear
territories. The chromosome territories have been proposed to be further subdivided into two
mutually excluded compartments called ‘A’ (active) and ‘B’ (inactive) with distinct accessibilities. Each
compartment was reported to consist of multiple topologically associating domains (TADs) (reviewed
in [1]). Within TADs, DNA/chromatin looping was predicted to promote higher DNA interaction
frequencies among DNA sites located far apart within the linear DNA molecule (reviewed in [1]).
Epigenetic chromatin modifications, including DNA and histone modifications, were shown to
control genome accessibility [2] and, thus, the spatial-temporal gene expression without changing
the nucleotide sequence. DNA methylation, established by DNA methyltransferases, blocks the
access of multiple factors to DNA, thus creating repressive regions. This DNA modification is read
by methyl-CpG binding domain (MBD) protein family, which in addition recruit specific chromatin
modifiers (reviewed in [3]). Methyl-CpG binding protein 2 (MeCP2) was the first member of the MBD
family to be identified [4] and the most extensively studied one. Hereafter, we will focus on MeCP2
isoforms, domains, interactions, modifications and mutations before moving to its role in higher order
chromatin organization.
2. MeCP2 Interactions, Modifications and Mutations
2.1. MeCP2 Isoforms and Domains
The MeCP2 gene is highly conserved in Euteleostomi (bony vertebrates) and in humans is located
on the X chromosome. Mutations in the MeCP2 gene were linked to the human neurological disorder
Rett syndrome (RTT) [5]. The MeCP2 protein has two isoforms (MeCP2 e1 (exon 1) and MeCP2 e2
(exon 2)) with different amino termini due to alternative splicing and different translational start
sites. The two isoforms of MeCP2 are abundantly expressed in the central nervous system, but with
different expression levels and distributions in developing and post-natal mouse brains. MeCP2 e1 is
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the predominant isoform in brain and has an earlier expression onset than MeCP2 e2 [6]. The two
isoforms are commonly considered as functionally equivalent, yet recent evidence shows that MeCP2
e1 plays a role in neuronal maturation [7] and is more relevant for RTT [8–10]. In view of the fact
that MeCP2 e2 isoform was the first to be known and a much larger body of literature pertains to this
isoform, we will, throughout, use amino acid coordinates from MeCP2 e2 isoform.
Both variants include two functionally characterized domains: the methyl-CpG binding domain
(MBD) and the transcriptional repression domain (TRD). The MBD specifically recognizes and binds
5-methylcytosine (5mC), while the TRD was found to bind multiple transcriptional repressors, thus
silencing gene expression [11–16]. However, the TRD was also shown to bind to multiple transcriptional
activators and activate gene expression [17–19]. More recently, the TRD has been narrowed down to
the N-CoR/SMRT interacting domain (NID) [20]. A summary of the best characterized domains of
MeCP2 is shown in Figure 1. The DNA binding properties of the different domains and the mechanism
of DNA binding will be addressed in the next section.
2.2. MeCP2 DNA Binding
Early studies on MeCP2 characterized it as a protein being capable to bind to a single, symmetrically
methylated CpG pair via the MBD domain spanning amino acids 89 – 162 and thereby overlapping
approximately twelve base pairs of DNA [4,21,22]. Later studies indicated that the N-terminal domain
(NTD) enhanced DNA binding affinity via the MBD [23], while the intervening domain (ID), TRD and
C-terminal domain (CTD) alpha showed methylation-independent DNA binding capabilities and CTD
beta was proposed to bind to chromatin, but not to naked DNA [23,24]. Furthermore, three AT-hook-like
domains were identified within the ID, TRD and CTD alpha domains (AT-hook 1, aa 184–195; AT-hook
2, aa 264–273; AT-hook 3, aa 341–364). The AT-hook motif is a short motif binding to the minor groove of
AT-rich DNA via the core consensus amino acid sequence RGRP [25]. These methylation-independent
DNA binding capabilities allow MeCP2 to bind to different sites on the DNA at the same time, thus,
possibly contributing to genome-wide chromatin organization. With the exception of the MBD, MeCP2
was shown to be mostly an intrinsically disordered protein. Upon binding to DNA, though, increased
secondary structure in ID and TRD were observed [23]. The MBD is the only domain showing
structurally conserved motifs, as it contains four beta-sheets and one alpha-helix building up a wedge
shape with a beta-sheet face presenting positively charged amino acids for interaction with the DNA
as determined by nuclear magnetic resonance analysis [26]. Accordingly, this domain showed only
minor conformational changes as a result of DNA binding [23,26]. The subsequent crystal structure
of the MBD bound to the Bdnf gene promotor revealed that MBD mCpG interaction might involve
five water molecules, leaving only three amino acids with direct contact to the DNA: D121, R111 and
R133 [27]. In line with this study, these amino acids were found mutated in RTT and with significantly
reduced MeCP2 DNA binding [27–29].
Dynamic structural analysis of MeCP2 using H/DX-MS, led to the proposal that the intrinsically
disordered MeCP2 samples multiple conformational states, also during non-specific interaction with
the DNA [30].
Using genome wide chromatin immunoprecipitation-sequencing (ChIP-seq) analysis, MeCP2 was
found to bind globally across the genome tracking mCpG density [31]. Furthermore, in purified nuclei
from mouse brain MeCP2 was shown to be expressed at near histone octamer levels [31]. These findings
suggest that MeCP2 binds globally across the genome reducing transcriptional noise.
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Nevertheless, MeCP2 was also described to bind to actively transcribed unmethylated DNA
in vivo [17,32] with only a minor portion of MeCP2-bound promoters being highly methylated [32].
A possible explanation would be that MeCP2 folds upon binding to DNA and scans the DNA for
suitable binding sites making use for this of its non-specific DNA binding sites [23,33]. Thus, it would
only bind non-specifically to active genes to scan the DNA for mCpG binding sites.
Recently, MeCP2 was reported to bind not only mCpG but also mCpApC [34]. The patterns of
mCpApC differ between neuronal cell types and may, thus, contribute to cell type specific effects of
MeCP2 [35,36].
In addition to binding DNA and methylated cytosines, MeCP2 was proposed to bind to
5-hydroxymethylcytosine (5hmC) in mouse brain [37] and embryonic stem cells [38]. 5hmC is an
oxidation product of 5mC and can be further oxidized to 5-formylcytosine (5fC) and 5-carboxylcytosine
(5caC) by TET (ten-eleven-translocation) proteins, which might enable active DNA demethylation
by different pathways (reviewed in [39]). In addition, 5hmC levels were reported to be differentially
distributed between different tissues, much lower than 5mC levels and associated to actively expressed
and developmentally regulated genes [40]. Nevertheless, these findings are highly debated, as the
results are tissue and cell type dependent [37,38], the recognition mechanism of 5hmC by MeCP2 is
unclear and other studies hint to a binding affinity similar to binding unmethylated DNA [41–43].
A more indirect way of MeCP2 to repress transcription by DNA binding is the protection of
MeCP2 bound 5mC against oxidation to 5hmC by TET enzymes by restricting their access to the
methylated cytosine [44]. This was proposed to contribute to restricting transcriptional noise [31]
and, in particular, repressing tandem repeat DNA expression [44] and L1 retrotransposition [45–47].
TET-mediated L1 activation was shown to be prevented by binding of MeCP2 to 5mC [47].
Summarizing, methylation-specific and unspecific MeCP2 DNA binding are both essential for its
function in transcriptional repression and chromatin organization, and its multifunctional domain
structure allows the protein to simultaneously bind to DNA and interact with other proteins, which will
be described next.
2.3. MeCP2 Protein–Protein Interactions
Interactions of MeCP2 with several proteins mediate and regulate its multiple functions in
transcriptional regulation, chromatin organization and RNA splicing. An overview of interacting
proteins, the interacting MeCP2 regions and the function of these interactions is presented in Figure 1
and Table 1.
One major mechanism by which MeCP2 represses transcription is by recruiting corepressor
complexes to methylated DNA. One such complex contains mSin3A and histone deacetylases
(HDACs), suggesting that transcriptional repression may in part rely on histone deacetylation [11,12],
e.g., by removing active chromatin marks. mSin3A was shown to be the direct MeCP2 binding partner,
whereas HDACs showed a weaker binding affinity to MeCP2 and, thus, might bind via mSin3A [11].
Another corepressor complex reported to interact with MeCP2 is the NCoR/SMRT interacting with a
small region within the TRD domain, which was thus called NID. The data suggested that MeCP2
recruited NCoR/SMRT to methylated DNA and that this MeCP2 bridge function is disturbed in
RTT [20]. Interestingly, binding of Sin3A was not disrupted by NID mutations [20].
In addition to transcriptional repression, MeCP2 might also work as an activator, as it was found
associated with the transcriptional activator CREB1 (cyclic AMP-responsive element-binding protein
1) at the promoter of an activated gene [17]. In gene expression analysis from mouse hypothalami, the
gain of MeCP2 was shown to result in more transcriptional activation than repression, whereas MeCP2
loss lead to reverse effects [17]. These results are in line with a previous study, where only a minor
portion of MeCP2 was found bound to methylated CpGs, but 63% of MeCP2 were bound to actively
expressed promoters [32]. In other studies though, MeCP2 was found to track methylated CpGs
genome wide [31], as described above.
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As transcriptional activity is influenced by chromatin organization, these MeCP2 functions can
hardly be separated. By interacting with histone methyltransferase acting on histone H3 lysine 9, MeCP2
was reported to target histone methylation to methylated regions on the DNA [48]. As mentioned
above, MeCP2 transcriptional repression involves recruitment of histone deacetylases and deacetylation
of histones is likely followed by histone methylation [48], thus switching chromatin from an active to a
repressive state. Histone methylation may result in recruitment of other proteins like heterochromatin
protein 1 (HP1), thus reinforcing the repressed chromatin state [49,50]. MeCP2 and HP1 were shown to
interact [51] and both were reported to associate with SUV39H1 (suppressor of variegation 3-9 homolog
1) histone methyltransferase [13,52], which methylates histone H3 lysine 9. In addition, MeCP2 might
be involved in regulation of maintenance DNA methylation by DNMT1 (DNA methyltransferase 1), as
the interaction of both proteins was also described [53]. DNMT1 interacts with HDAC1 and 2 [54,55],
and was shown to replace the mSin3A-HDAC complex upon MeCP2 binding [53].
Another mechanism by which MeCP2 modulates chromatin architecture could be oligomerization.
In that regard, MeCP2 was shown to associate with itself and the methyl CpG binding domain
protein 2 (MBD2) [56]. Furthermore, MeCP2 associates with the chromatin remodeling protein
ATRX (alpha-thalassemia/cognitive disability syndrome X-linked). Analysis of MeCP2 null mouse
brains showed delocalization of ATRX from heterochromatic foci, suggesting a MeCP2-dependent
ATRX targeting to heterochromatic regions in mature neurons [57]. As the MeCP2 mediated ATRX
targeting to heterochromatin took place only in mature neurons where MeCP2 is very abundant [57],
this underscores the relevance of MeCP2 level for its function.
MeCP2 might also play a functional role in RNA splicing, as it binds to WW domains of the splicing
factors FBP (formin-binding protein) 11 and HYPC (Huntington yeast partner C) via a proline rich
domain in the MeCP2 C-terminus [58,59]. Genotype-phenotype studies on RTT frameshift mutations
support the hypothesis that disruption of the proline-rich region in the MeCP2 C-terminus, thus
abolishing its binding to FBP11 and HYPC, contributes to Rett phenotype [59]. In addition, association
of MeCP2 with the Y box-binding protein 1 (YB-1), a conserved DNA and RNA binding protein [60],
promotes exon inclusion in YB-1 responsive CD44-splicing reporter assays [60]. This leads to the
proposal that misregulation of transcription as well as splicing might contribute to RTT [60].
Although several MeCP2 interaction partners were identified so far, the whole network of
protein-protein interactions, their interplay and the entire composition of MeCP2 transcription silencing
compartments require further investigation. Importantly, MeCP2 DNA binding and protein-protein
interactions need to be studied in the context of post-translational modifications as these can abolish or
enhance DNA and protein binding, thus, ultimately influencing chromatin organization.
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Table 1. Rectangles indicate proteins with no mapped interaction region within MeCP2. NTD: N-
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Figure 1. Overview of MeCP2 interaction partners. MeCP2 interaction partners, group by main
function and ordered by where they interact within MeCP2, if known. References are given in Table 1.
Rectangles indicate proteins with no mapped interaction region within MeCP2. NTD: N-terminal
domain; MBD: methyl binding domain; ID: intervening domain; NID: N-CoR interacting domain; CTD:
C-terminal domain; TRD: transcriptional repression domain. Amino acid labeling according to mouse
MeCP2 isoform e2. Protein domain structure generated using DOG 1.0 software [61].
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Table 1. MeCP2 interaction partners and function upon interaction.
Interactor MeCP2 Function Upon Interaction References
Transcriptional
repression
HP.1 repression, formation of subcellular silencing compartments Agarwal et al., 2007 [51]
PU.1 formation of repression complex, possibly recruitment of mSin3A-HDAC Suzuki et al., 2003 [15]
Dnmt1 association with MeCP2 contributes to maintenance methylation Kimura & Shiota 2003 [53]
LANA MeCP2 directs LANA to chromocenters, might contribute toLANA-mediated repression Matsumura et al., 2010, Krithivas et al., 2002 [62,63]
ATRX targeting to heterochromatic regions in mature neurons, silencing ofimprinted genes; possibly control of nucleosome positioning
Nan et al., 2007,
Kernohan et al., 2010 [57,64]
Sin3A transcriptional repression, corepression complex with HDAC and MeCP2 Nan et al., 1998,Jones et al., 1998 [11,12]
YY1 cooperation in repression Forlani et al., 2010 [16]
c-Ski transcriptional repression Kokura et al., 2001 [14]
MBD2 heterointeractions, might increase heterochromatin clustering Becker et al., 2013 [56]
MeCP2 homointeractions, might increase heterochromatin clustering Becker et al., 2013 [56]
N-CoR recruitment of N-CoR/SMRT to methylated DNA, bridge function of MeCP2 Kokura et al., 2001,Lyst et al., 2013 [14,20]
Brahma transcriptional repression Harikrishnan et al., 2005 [65]
CoREST transcriptional repression possibly involving REST, CoREST, MeCP2,SUV39H1 and HP1 Lunyak et al., 2002 [13]
CREB transcriptional activation Chahrour et al., 2008 [17]
LEDGF/p75 might differentially influence gene activation Leoh et al., 2012 [18]
SMC1, SMC3 interaction with MeCP2, ATRX, might promote repression by loop formation Kernohan et al., 2010, Gonzales et al., 2012 [19,64]
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Table 1. Cont.
Interactor MeCP2 Function Upon Interaction References
RNA interaction
Prpf3 RNA binding, possibly involved in splicing Long et al., 2011 [66]
mRNA, siRNA not known Jeffrey et al., 2004 [67]
YB-1 RNA-dependent complex, regulation of splicing Young et al., 2005 [60]
Sdccag1 not known Long et al., 2011 [66]
FBP11 not known Buschdorf & Stratling 2004, Bedford et al., 1997[58,59]
HYPC not known Buschdorf & Stratling 2004 [59]
post-translational
modifiers
H3K9 MT targeting of histone methylation to methylated DNA Fuks et al., 2003,Lunyak et al., 2002 [13,48]
SUV39H1 association with MeCP2 might contribute to silencing by methylation ofH3K9, creating HP1 binding sites Lunyak et al., 2002 [13]
HDAC 1/2 histone deacetylases form corepression complex with MeCP2 and Sin3A Nan et al., 1998,Jones et al., 1998 [11,12]
HIPK2, HIPK1 kinases might phosphorylate MeCP2 on S80 and S216 Bracaglia et al., 2009, Lombardi et al., 2017 [68,69]
PARP poly(ADP-ribosyl)ation reduces MeCP2 heterochromatin clustering ability Becker et al., 2016 [70]
CDKL5 association in vitro, phosphorylation of MeCP2 by CDKL5 unclear(opposing results in the two publications)
Mari et al., 2005,
Lin et al., 2005 [71,72]
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2.4. MeCP2 Post-Translational Modifications
Recently, several MeCP2 post-translational modifications (PTMs) were reported, mostly in large
scale proteomic studies focusing on mapping one specific PTM in the whole proteome. In Table 2,
experimentally determined MeCP2 modifications are summarized, together with the species in which
they were identified, the methods used for identification along with references. A more detailed list
can be found on PhosphoSitePlus.org [73], including additional sites only available as curated datasets.
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Table 2. Summary of MeCP2 post-translational modifications.
Residue* Modification Species MS/Other Methods References**
NTD
K12 ubi human x/- Gonzales et al., 2012 [19]
S13 phos human, mouse x/- Gonzales et al., 2012, Humphrey et al., 2013, Shiromizu et al., 2013 [19,74,75]
S53 phos human x/- Shiromizu et al., 2013, Bian et al., 2014, Sharma et al., 2014 [75–77]
S68 phos mouse x/- Huttlin et al., 2010 [78]
S70 phos mouse, human x/- Huttlin et al., 2010, Mertins et al., 2016 [78,79]
S78 phos human, mouse, rat x/- Dephoure et al., 2008, Zanivan et al., 2008, Tweedie-Cullen et al., 2009 [80–82]
S80 phos human, mouse, rat x/x Zhou et al., 2006, Tao et al., 2009, Bracaglia et al., 2009 [68,83,84]
K82 ubi human x/- Gonzales et al., 2012 [19]
S86 phos mouse, human x/x Ebert et al., 2013, Mertins et al., 2014 [85,86]
MBD
R115 met human x/- Geoghegan et al., 2015 [87]
S116 phos human x/- Dephoure et al., 2008, Kettenbach et al., 2011, Sharma et al., 2014 [77,80,88]
K119 ubi, dimet human x/- Gonzales et al., 2012, Jung et al., 2008 [19,89]
Y120 phos human, mouse x/x Dephoure et al., 2008, Bergo et al., 2015, D’Annessa et al., 2018 [80,90,91]
K130 ubi human x/- Wagner et al., 2011, Gonzales et al., 2012 [19,92]
K135 ubi human x/- Gonzales et al., 2012 [19]
T148 phos mouse x/- Tao et al., 2009 [84]
S149 phos mouse, human x/- Tao et al., 2009, Olsen et al., 2010, Kettenbach et al., 2011 [84,88,93]
T160 phos mouse x/- Tweedie-Cullen et al., 2009 [82]
R162 met mouse, human x/- Guo et al., 2014, Larsen et al., 2016 [94,95]
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Table 2. Cont.
Residue* Modification Species MS/Other Methods References**
ID
163–206 PAR human, mouse, rat x/x Jungmichel et al., 2013, Becker et al., 2016 [70,96]
S164 phos mouse x/x Tao et al., 2009, Tweedie-Cullen et al., 2009, Stefanelli et al., 2016 [82,84,97]
S166 phos mouse, human x/- Huttlin et al., 2010, Yi et al., 2014, Mertins et al., 2014 [78,86,98]
S178 phos human x/- Shiromizu et al., 2013 [75]
T184 phos human, mouse x/- Mertins et al., 2014 [86]
T203 phos human x/- Carrier et al., 2016 [99]
S204 phos human x/- Carrier et al., 2016 [99]
K210 dimet human x/- Jung et al., 2008 [89]
S216 phos human (mouse, rat) x/x Olsen et al., 2010, Kettenbach et al., 2011, Lombardi et al., 2017 [69,88,93]
K219 acet rat x/- Lundby et al., 2012 [100]
K223 ubi human x/- Akimov et al., 2018 [101]
K223 SUMO mouse -/x Cheng et al., 2014 [102]
T228*** phos human x/- Mertins et al., 2014 [86]
S229 phos human, rat (mouse) x/x Zhou et al., 2006, Chen et al., 2009, Gonzales et al., 2012 [19,83,103]
K233 ubi human x/- Gonzales et al., 2012 [19]
244–275 PAR human, mouse, rat x/x Jungmichel et al., 2013, Becker et al., 2016 [70,96]
K249 ubi human x/- Gonzales et al., 2012 [19]
K256 ubi human x/- Gonzales et al., 2012 [19]
K267 met human x/- Wu et al., 2015 [104]
NID
K271 ubi human x/- Gonzales et al., 2012 [19]
S274 phos mouse (human) x/x Tweedie-Cullen et al., 2009, Humphrey et al., 2013, Ebert et al., 2013 [74,82,85]
S292 phos mouse, rat x/x Humphrey et al., 2013, Liu et al., 2015 [74,105]
S295 phos mouse x/- Humphrey et al., 2013 [74]
K305 ubi human x/- Gonzales et al., 2012 [19]
K307 ubi, acet human x/- Gonzales et al., 2012 [19]
T308 phos mouse -/x Ebert et al., 2013 [85]
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Table 2. Cont.
Residue* Modification Species MS/Other Methods References**
CTD
T311 phos mouse, human x/- Huttlin et al., 2010, Mertins et al., 2014, Parker et al., 2015 [78,86,106]
S313 phos human, mouse x/- Bian et al., 2014, Sharma et al., 2014, Parker et al., 2015 [76,77,106]
K321 acet, ubi human, mouse x/- Gonzales et al., 2012, Beli et al., 2012, Weinert et al., 2013 [19,107,108]
T327 phos human x/- Shiromizu et al., 2013 [75]
S341 phos mouse x/- Humphrey et al., 2013 [74]
K347 met human x/x Dhayalan et al., 2011, Wu et al., 2015 [109,110]
S357 phos human x/- Yang et al., 2006 [111]
S359 phos human x/- Yang et al., 2006, Bian et al., 2014 [76,111]
S360 phos human, mouse x/- Yang et al., 2006, Grimsrud et al., 2012, Humphrey et al., 2013 [74,111,112]
S393 phos human x/- Bian et al., 2014 [76]
S399 phos mouse, rat, human x/- Tao et al., 2009, Gonzales et al., 2012 [19,84]
S421 phos mouse, rat(human) x/x Zhou et al., 2006, Tao et al., 2009, Deng et al., 2010 [83,84,113]
S424 phos human, rat, mouse x/x Dephoure et al., 2008, Tao et al., 2009, Li et al., 2011 [80,84,114]
T434 gl rat, mouse x/- Wang et al., 2010, Alfaro et al., 2012, Trinidad et al., 2012 [115–117]
T441 gl mouse x/- Alfaro et al., 2012 [116]
T443/T444*** gl rat x/- Wang et al., 2010 [115]
K447 acet human x/- Choudhary et al., 2009, Beli et al., 2012, Wu et al., 2015 [104,107,118]
T477 phos human x/- Sharma et al., 2014 [77]
S484 phos human, mouse x/- Kettenbach et al., 2011, Schweppe et al., 2013, Mertins et al., 2014 [86,88,119]
Modifications identified by mass spectrometry (MS) might have unclear localization. x means the method as listed above was used, - means it was not used. * modification numbering
according to mouse MeCP2 isoform starting in exon 2 (mouse: 484 aa, human: 486 aa, rat: 492 aa) ** references only exemplary (for more information see PhosphositePlus.org) *** residue
numbering according to species mentioned as it differs from mouse.
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Most of the modifications were identified in large scale studies and not further validated by any
other assay. Furthermore, in most cases no additional information is available regarding their influence
on MeCP2 function (e.g., [74–77,87,88,92]). Many of these PTMs were mapped using a single cell line
(e.g., [74,77,88]), and their existence in vivo has not been demonstrated. For these reasons, we will
focus here on the more detailed studies providing validation and functional relevance of MeCP2 PTMs,
in particular, within the context of chromatin.
The first phosphorylation (phos) site identified on MeCP2 was mapped to the CTD on serine 421.
S421phos was found as an upshifted band on Western blot analysis upon membrane depolarization [83,
120,121] and occurring exclusively in brain, although MeCP2 was detected in many other tissues [122].
S421A/S424A double mutant mice showed better performance in hippocampal memory tests, enhanced
longterm potentiation [114] and increased locomotor activity [84]. Analysis of Mecp2 S421A mice
revealed an increased dendritic complexity, and defects in the response to novel experiences [123].
As global S421phos was observed upon membrane depolarization, this modification might not regulate
expression of specific genes, but rather be involved in modulating global response to membrane
depolarization [123].
Together with S421phos, S80phos within the NTD is one of the most studied MeCP2
phosphorylation sites with functional characterization. In contrast to S421 phosphorylation, serine 80
was reported to be dephosphorylated upon membrane depolarization and S80A mutant mice show
decreased locomotor activity [84]. The modification is highly enriched in the brain and ubiquitously
distributed similar to total MeCP2 [84]. S80A mutation decreased MeCP2 chromatin binding affinity,
although the MeCP2 S80A protein levels and subcellular distribution did not differ relative to the
wildtype MeCP2. Thus, it was suggested that the phosphorylation possibly fine-tunes chromatin
association [84]. The homeodomain-interacting protein kinases 1 (HIPK1) and 2 (HIPK2) were proposed
to be responsible for MeCP2 phosphorylation at serine 80 [68,69].
Another MeCP2 phosphorylation site influencing chromatin binding affinity was identified on
tyrosine 120 within the MBD domain of MeCP2. This tyrosine residue is substituted in a RTT patient by
aspartic acid [124], which could mimic the phosphorylated state. MeCP2 Y120D mutation was found
to cause a decrease in binding affinity of MeCP2 to heterochromatin [28]. This could be explained
at the structural level by computational modeling indicating that MeCP2 Y120D drastically reduces
MeCP2 affinity for DNA as compared to wildtype MeCP2 [91].
A conserved serine (S164) located at the beginning of ID just after the MBD, was shown to be
abundantly phosphorylated in the brain in a developmentally regulated manner [97]. While the
phospho-mimicking version S164D showed minor binding to chromatin in live-cell kinetic studies,
the phospho-defective mutation S164A had the opposite effect [97]. These results could be explained
by in silico modeling of the 3D structure of this phosphorylation site, revealing the addition of negative
charge to the protein surface as a consequence of S164 phosphorylation, hence, decreasing DNA
binding. Immunofluorescence analysis of wildtype neurons versus MeCP2 S164 mutants revealed
that temporal regulation of S164 phosphorylation is required for proper nuclear size and neuronal
dendritic branching [97].
In addition to phosphorylation, poly(ADP-ribosyl)ation (PAR) of MeCP2 at the ID and TRD
domains was reported to occur in vivo in the mouse brain and to influence heterochromatin structure.
The addition of this anionic modification within the two highly cationic MeCP2 protein domains
responsible to bind DNA was proposed to lead to a general decrease in DNA binding affinity [70].
Concomitantly, poly(ADP-ribosyl)ation of MeCP2 was shown to reduce binding and clustering of
pericentric heterochromatin in cell-based assays, suggesting a role of this PTM in MeCP2 chromatin
architecture regulation [70].
Altogether, MeCP2 modifications have been shown to regulate its ability to bind and organize
DNA/chromatin, as they change the molecular properties of the respective amino acids, which can be
critical depending on the position of the residue within the MeCP2 domains. Yet, as mentioned above,
most of the modifications identified in MeCP2 have not been functionally characterized and their role
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in RTT is unclear. The next section will address the consequences of MeCP2 mutations occurring in the
context of RTT.
2.5. MeCP2 RTT Mutations
MeCP2 was shown to be associated with the neurological disorder Rett syndrome (RTT),
as mutations in this gene were found in about 80% of RTT patients [5]. RTT affects mostly young girls
and is characterized by normal development until 7-18 months of age, followed by a developmental
stagnation and decline of higher brain functions [125]. Mutations causing RTT and related neurological
disorders have been identified along the entire MeCP2 locus, but effects vary depending on the
mutation type and location. Missense and nonsense mutations are the most commonly found
and relatively well studied. A collection of all RTT related mutations can be found in the online
RettBASE: RettSyndrome.org (http://mecp2.chw.edu.au/cgi-bin/mecp2/search/printGraph.cgi). Figure 2
graphically summarizes the high frequency mutations causing RTT (Figure 2) and Table 3 describes
their phenotypes.
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Figure 2. Diagram showing the high frequency mutation spectrum in Rett syndrome patients.
A compendium of RTT mutations can be found in the online RettBASE. Missense mutations are shown
above and nonsense mutations below the scheme showing the structure of MeCP2 (MeCP2 domains
as in Figure 1). X means point mutation to stop codon, thus generating a truncated protein. Amino
acids and substitutions are given according to the single-letter nomenclature. Mutation numbering
according to human MeCP2 isoform starting in exon 2.
In the following, we will concentrate on RTT mutations impacting MeCP2 DNA binding and
chromatin organization function.
MeCP2 RTT related missense mutations are largely found in the MBD, and a large proportion of
these mutations reduce the 5mC binding affinity and, consequently, lead to impaired heterochromatin
organization and function in cells [28].
MeCP2 R133 and R111 residues located within the MDB directly contact 5mC, and mutations at
either site decrease MeCP2 localization at heterochromatin in vivo albeit to different extent. MeCP2
R111G is a rare RTT mutation found only in one patient, which abolishes MeCP2 localization to
heterochromatin [28]. MeCP2 R133 mutation influences the pericentric heterochromatin localization
depending on the amino acid substitution. MeCP2 R133C and R133L decrease the enrichment at
heterochromatin, whereas R133H promotes it [28,29]. Furthermore, artificially targeting MeCP2 R111G
and R133L mutants to pericentric heterochromatin rescued their ability to cluster heterochromatin [29].
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Table 3. Summary of high frequency RTT-related MeCP2 point mutations and phenotypes.
Mutation Frequency Effect on: Mice, Cell, Protein References
MBD
R106W 132 Protein: Abolished methyl-DNA binding ability. Ballestar et al., 2000 [126]
R106Q 21 Protein: Reduced methyl-DNA binding ability. Yang et al., 2016 [127]
R133C 217 Mice: Decreased life span of 42 weeks and body weight.Protein: Reduced chromatin binding ability. Brown et al., 2015 [128]
S134C 21 Protein: Decreased stability and folding, reduced methyl-DNA binding. Yang et al., 2016 [127]
A140V 28
Mice: Late onset cognitive regression, pyramidal symptoms, parkinsonism, and bipolar
symptoms.
Increased cell packing density, abnormal dendritic branching of neurons.
Life span: >14 months.
Cell: Smaller neuron size.
Down-regulation of the mTOR signaling pathway.
Protein: Increased folding stability.
Venkateswaran et al., 2014
Jentarra et al., 2010
Ma et al., 2014
Sampathkumar et al., 2016
Yang et al., 2016 [127,129–132]
P152R 71 Protein: Decreased stability and folding, reduced methyl-DNA binding. Yang et al., 2016 [127]
T158M 419
Mice: Decreased life span of 13 weeks and body weight.
Disturbed nucleolin subcellular localization.
Cell: Reduced neurite outgrowth, reduced dendritic complexity, and impaired
mitochondrial health in forebrain neurons, reduced CREB and phosphorylated CREB levels.
Protein: Decreased protein stability and methyl-DNA binding ability.
Lundvall et al., 2006
Olson et al., 2018
Bu et al., 2017
Chapleau et al., 2009
Brown et al., 2015 [128,133–136]
ID
R168X 364
Mice: Breathing dysfunction, hind limb clasping and atrophy, hypoactivity.
Decreased life span of ~12 weeks.
Male mice: Impaired motor and cognitive function and reduced anxiety, abnormal hypoxic
and hypercapnic responses, apnea incidence, irregular breath cycle and decreased breathing
rate, enriched outside chromocenters.
Protein: Decreased chromatin compaction ability, decreased methyl-DNA binding.
Lawson-Yuen et al., 2007
Schaevitz et al., 2013
Bissonnette et al., 2014
Georgel et al., 2003
Yusufzai et al., 2000 [137–141]
R255X 313
Mice: Decreased brain weight, increased breathing, incidence of arrhythmia, anxiety, motor
and learning impairments.
Cell: mTORC1 pathway abnormalities, decreased nucleolin level, increased
phosphorylation of mTORC2 (S2481) and mTORC1 (S2448).
Protein: Decreased methyl-DNA binding.
Pitcher et al., 2015
Olson et al., 2018
Yusufzai et al., 2000
[134,141,142]
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Table 3. Cont.
Mutation Frequency Effect on: Mice, Cell, Protein References
NID
R270X 274
Male: Severe neonatal encephalopathy and death before 4 years of age.
Mice: Median life span of 85 days, increased body weight, decreased brain weight.
Cell: Less athalassemia/mental retardation syndrome X linked (ATRX) foci.
Protein: Decreased methyl-DNA binding, failed to form a higher order structure with
nucleic acids and reduced activity to oligomerize nucleic acids.
Villard et al., 2007
Baker et al., 2013
Yusufzai et al., 2000
[141,143,144]
R294X 237 Cell: Induce caspase mediated apoptosis, rescued by FoxG1.Protein: Decreased methyl-DNA binding; decreased stability.
Lundvall et al., 2006
Yusufzai et al., 2000 [133,141]
R306C 245
Mice: Hind limb clasping, impaired mobility and motor coordination, reduced brain weight
and size.
Cell: Loss of interaction with NCoR/SMRT.
Protein: Loss of T308 phosphorylation.
Lyst et al., 2013 [20]
X means point mutation generating a truncated protein. Mutation numbering according to human MeCP2 isoform starting in exon 2.
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T158 is the most frequently found MeCP2 MBD mutation site in RTT patients and two substitutions
have been reported, T158M (frequency 419) and T158A (frequency 2). Neurons expressing MeCP2
T158M showed reduced neurite outgrowth and dendritic complexity by down regulating the expression
and phosphorylation of transcriptional activator CREB1 [135,136]. Both MeCP2 T158M and T158A
proteins show decreased stability, methyl-DNA binding ability and heterochromatin clustering
function [28,128,139,145].
TRD is a second mutational hotspot domain in MeCP2. Considering its function in direct
interaction with multiple transcriptional repressor complexes (see Figure 1 and Table 1), mutations
within this region are considered to influence the recently proposed MeCP2 ‘bridge’ function between
repressors and chromatin [20,146].
R306C is the most frequent missense mutation found within the MeCP2 TRD. Mutant mice
expressing MeCP2 R306C showed typical RTT phenotype: hind limb clasping, impaired mobility and
motor coordination, reduced brain weight and size [147]. This mutation did not influence the MeCP2
methyl-DNA binding ability in vitro [128], but showed decreased MeCP2 DNA occupancy in vivo [147],
and lack of interaction with NCoR/SMRT [85]. R306C also abolished (neuronal activity-dependent)
phosphorylation at the nearby T308 residue. The effect of losing T308 phosphorylation was tested by
creating a MeCP2 T308A knock-in mouse model and the analysis of these mutant mice indicated that it
contributes to some of the neurological deficits in RTT [85]. Yet, it is still unclear whether the mutation
of residue R306 has an influence on chromatin structure.
In addition to missense mutations, several nonsense RTT mutations have been described within
the ID or the TRD. In general, these truncations showed decreased protein stability in vivo and DNA
binding affinity in vitro [141].
MeCP2 R168X generates a truncated protein with a deletion of the complete TRD and C-terminal
region. Male and female mice with R168X expression showed typical RTT phenotype, but little is known
about the underlying mechanism. Although the entire MBD is retained, MeCP2 R168X has impaired
ability to form higher order structures as tested by in vitro nucleosomal array (NA) assays [140].
The functional importance of the MeCP2 AT-hooks is highlighted by a comparative study in mice
expressing either MeCP2 R270X or MeCP2 G273X (a truncation found in only one male RTT patient),
which yielded a different developmental rate and phenotypic progression [148]. MeCP2 R270X mutant
mice survived less time than MeCP2 G273X (85 days and 201 days, respectively) due to a disrupted
AT-hook 2 (aa 264-273) in the MeCP2 R270 truncation. AT-hook 2 disruption decreased the ability
of MeCP2 to promote oligomerization of NA in vitro and mislocalization of chromatin-remodeling
protein ATRX in vivo [144].
In summary, the severe phenotypes of RTT patient mutations described above emphasize how
essential protein stability, DNA/methyl cytosine binding, interactions with other proteins and ultimately
chromatin organization are for proper MeCP2 function in vivo.
3. MeCP2 in Higher Order Chromatin Compartmentalization
MeCP2 is a multifunctional epigenetic reader regulated at multiple levels including, as reviewed
above, specific isoforms, interacting factors, post-translational modifications and their interplay within
the chromatin context. Yet, it is not well understood how MeCP2 orchestrates genome architecture.
In this section, we will summarize findings related to the role of MeCP2 on higher order chromatin
organization and propose a unifying model.
3.1. MeCP2 and Chromatin Looping
MeCP2 was described to compact nucleosomal arrays (NAs) [140] and to form loops
involving undersaturated (DNA partially occupied by nucleosomes) nucleosomal arrays in vitro [24].
While wildtype MeCP2 was shown to form nucleosome-MeCP2-nucleosome ‘sandwich’ structures
bringing two nucleosomes closely together, the RTT truncation mutant R294X was shown to form
DNA-MeCP2-DNA ‘stem’ motifs, bringing nucleosome entry and exit site in close proximity [24].
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Interestingly, the RTT mutation R106W, which does not bind to methylated DNA (see Table 3), did not
induce any chromatin conformations. Thus, MeCP2 loop formation was proposed to proceed in a two
step process involving methylation-dependent DNA binding followed by methylation-independent
interactions between MeCP2 CTD and nucleosomes [24]. Of note, MeCP2 was also shown to bind to
four-way junction DNA, which has a similar conformation as the ‘stem’ motif [24,149]. Importantly,
MeCP2 was proposed to be involved in the formation of a silent chromatin loop at the imprinted
Dlx5-Dlx6 locus, and this loop is lost in RTT [150].
Current models though propose that the chromatin loops are promoted by ‘loop extrusion’,
where cohesin extrudes chromatin until it encounters boundaries created by CTCF (CCCTC-binding
factor) binding [151,152], albeit the underlying mechanism is unclear. MeCP2 has been reported to
interact with ATRX and cohesin subunits SMC1 (structural maintenance of chromosomes protein 1)
and SMC3 using coimmunoprecipitation experiments in mouse forebrain [64]. ATRX was proposed to
create an extended DNA linker region for CTCF binding [153], and CTCF was reported to promote
loop formation together with the cohesin complex [154,155]. Of note, the interaction of MeCP2 with
cohesin subunit SMC3 was found to be induced by S229 phosphorylation and inhibited by the S80
phosphorylation of MeCP2 [19], indicating a role of MeCP2 and its modifications on chromatin looping.
Contrary to MeCP2, it was frequently described that CTCF shows a decreased binding affinity
to methylated DNA [156,157]. Wang et al. found based on DNA methylome data from 13 cell types
that immortalized cells displaying DNA hypermethylation had elevated CTCF level [158]. This might
constitute a compensatory mechanism for lower CTCF binding due to hypermethylation [158] and may
rescue CTCF mediated insulation of known tumor suppressor genes against methylation dependent
silencing [159,160]. Furthermore, the 5mC oxidation product 5caC was found to enhance CTCF
association to DNA and facilitate binding to low affinity CTCF binding motifs [161,162]. As 5mC
oxidation to 5hmC followed by further oxidation to 5fC and 5caC was proposed to enable cytosine
demethylation ([163], see above), CTCF association to 5caC hints to a CTCF-based mechanism
reinforcing its own binding [162]. As MeCP2 has been shown to protect 5mC from TET mediated
oxidation [44], MeCP2 might, thus, influence CTCF binding and DNA loop formation.
As a conclusion, the potential structural and functional interactions between MeCP2 and CTCF
are still poorly understood and need to be clarified in further studies, especially considering the
importance of both proteins in regulation of chromatin structure and gene expression. Mechanistically,
loop formation has been proposed to give rise to TADs, whose boundaries are at least in part defined
by CTCF and cohesin [164]. Although there is no evidence directly showing any effects of MeCP2
on TADs, it is still noteworthy to explore if and how MeCP2 organizes TADs, considering the role of
MeCP2 on chromatin looping and counteracting CTCF binding.
3.2. MeCP2 and Heterochromatin Compartmentalization
Quantification of MeCP2 in neurons showed it to be nearly as abundant as histone octamers [31].
In MeCP2 deficient neurons, the level of histone H1 doubled [31], whereas in wild type neurons,
the H1 level was half of the amount of H1 in other cells [165], indicating that MeCP2 acts as a histone
H1-like chromatin linker. Accordingly, MeCP2 was shown: to accelerate H1 exchange in vivo, hence
decreasing dwell time of histone H1 in chromatin [166]; to have a similar mobility to H1 in vivo;
and to share with H1 an overlapping binding site on nucleosomes in vitro [31,166–168]. In fact, by
in vitro fluorescence anisotropy assays, it was observed that MeCP2 could replace histone H1 from
chromatin [166,169] and globally alter the chromatin state. MeCP2 deficiency was also reported to
affect global chromatin composition and state by increasing H3 acetylation [31]. Hence, MeCP2 was
proposed to dampen transcriptional noise from repetitive DNA elements including satellite DNA in
a DNA methylation-dependent manner [31]. MeCP2 was also shown to increase H3K9me2 at the
promoter of the SIRT1 gene [170] and MeCP2 inhibition was shown to decrease H3K27me3 levels on
silenced gene promoters [171], indicating a role of MeCP2 in facultative heterochromatin regulation.
Cells 2020, 9, 878 18 of 31
On the other hand, MeCP2 was also reported to activate gene expression by binding the transcription
activator CREB1 in euchromatin as mentioned above [17].
Based on the cytological analysis of DNA condensation level, eukaryotic chromatin can be
broadly divided into the actively transcribed, open euchromatin and the densely packed, repressed
heterochromatin. Heterochromatin is rich in methylated cytosines, which can be specifically recognized
by multiple epigenetic readers including MeCP2.
In vivo MeCP2 was shown to be enriched at pericentric heterochromatin [4]. Pericentric heterochromatin
is localized in proximity to the centromere and enriched in AT-rich major satellite DNA repeats occupying
about 10% of the mouse genome [172]. In the interphase nucleus, different pericentric heterochromatin
regions were shown to fuse and form locally extremely condensed regions called chromocenters [173],
a distinct, supra-chromosomal, membraneless heterochromatin domain also enriched in HP1 and H3K9me3.
As MeCP2 was shown to interact with HP1 and to colocalize with HP1 in heterochromatin [51] (Table 1),
this enables a cross talk between histone methylation and DNA methylation pathways strengthening
heterochromatin formation. The influence of MeCP2 in chromocenter organization was demonstrated by
Brero et al. [174], showing that, during myogenic differentiation, the number of chromocenters decreased,
i.e., heterochromatin clustered into larger compartments, concomitantly with increased MeCP2 level and
genome methylation. Of note, ectopic MeCP2-YFP could promote pericentric heterochromatin clustering
even in the absence of cellular differentiation.
Expanding from this initial study, the role of MeCP2 during neuronal differentiation was analyzed
comparing wild type and MeCP2 deficient mouse embryonic stem cells [175]. An increased MeCP2
level and enrichment at chromocenters was measured during neuronal differentiation, together with
significant chromocenter clustering. Accordingly, the chromocenter clustering function was impaired
in the MeCP2 deficient mouse embryonic stem cells. Furthermore, ectopic expression of MeCP2 with
RTT mutations showed impaired heterochromatin accumulation and decreased chromatin clustering
function [28], suggesting a role of heterochromatin organization in RTT.
At the molecular level, using in vitro nucleosomal arrays, Georgel et al. in 2003 observed by
electron microscopy that NAs formed both extensively condensed ellipsoidal particles and oligomeric
suprastructures upon addition of MeCP2. This was independent of DNA methylation and relying
upon regions downstream of MBD, as R168X truncation mutant failed to assemble oligomeric
suprastructures [140,176]. This was further confirmed by the observation that the ID, TRD and CTD
alpha could bind and compact NAs and that R270X and R273X, truncated within the TRD and missing
the whole CTD, could not compact and oligomerize NAs [23,144]. These facts could in part explain
how nonsense mutations of MeCP2 lead to severe symptoms of RTT.
It is still far from clear how MeCP2 organizes heterochromatin structure, but emerging evidence
suggests a role of phase separation in heterochromatin condensation.
3.3. Phase Separation and Heterochromatin Condensation
Compartmentalization of heterochromatin within the cell nucleus is evolutionarily conserved. Recent
evidence indicates that in eukaryotic cells, non-membrane bound compartments are present in both
the cytoplasm (e.g., stress granules [177]) and the nucleus (e.g., nucleoli [178]) and chromocenters [174].
Although described decades ago, how such membraneless compartments dynamically form and function
has been unclear. In 2009, Brangwynne et al. [179] proposed that germline P granules are liquid droplets
with fast exchange dynamics, fusion and fission properties and round appearance formed by liquid–liquid
phase separation [180], suggesting a possible mechanism for chromatin organization.
Proteins that could undergo phase separation often contain intrinsically disordered regions (IDRs)
or low complexity regions (LCRs) [181]. Chemically, the process is based on weak forces (mostly
hydrophobic interactions) and multiple electrostatic interactions including charge-charge, charge–pi,
pi–pi stacking interactions and hydrogen bonds [182–184]. Recent work implicates liquid-liquid
phase separation in the nuclear organization, leading to the formation of various subdomains with
distinct properties.
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An earlier in vitro cryo-electron microscopy study of purified simian virus 40 minichromosome
showed that the purified viral minichromosome was condensed into 10 nm globules. In high-salt
buffer, these globules showed the ability to fuse, whereas at low salt conditions, they opened into
filaments and nucleosome strings [185]. Maeshima et al. observed that NAs self-associate into globular
oligomers in a cation-induced manner, which can be modulated by histone H1 and linker DNA [186].
Altogether, these studies suggest a ‘liquid drop’ model of chromosome organization.
More recently, NAs were shown to undergo histone tail dependent liquid-like phase separation
in physiologic salt conditions, a phenomenon promoted by histone H1, controlled by linker DNA
length and disrupted by histone acetylation [187]. Furthermore, NAs with acetylated histones could
form a new liquid phase with multi-bromodomain proteins, and these droplets had distinct properties
compared to droplets formed by unmodified histones.
Two recent studies found that HP1alpha protein could drive chromocenter formation via phase
separation [188,189], linking phase separation to chromocenter structure and dynamics via multivalent
interactions. Interestingly, MeCP2 was shown to have a highly unstructured nature [33] and
to induce the formation of very large heterochromatin clusters when compared with HP1 [174].
Altogether, these studies suggest a framework to understand chromatin compartmentalization based
on liquid–liquid phase separation.
3.4. Model for MeCP2 Function in Chromocenter Clustering
In summary, as described in the sections above, MeCP2 interacts with DNA, methyl cytosines
and nucleosomes via separate domains, and interacts with several chromatin proteins. Furthermore,
MeCP2 can replace linker histone H1 and has a highly unstructured nature. Firstly, like most proteins
that could form liquid phase separation, MeCP2 intrinsically disordered regions consist of mainly
positively charged residues (arginines, histidines and lysines). These residues form electrostatic
interactions with the negatively charged amino acids in other proteins and phosphates in DNA or
RNA, thus, building multivalent protein-protein/DNA/RNA interactions. Such interactions locally
enrich or deplete factors in a dynamic manner, while being sensitive to post-translational modifications
(a described above). Secondly, MeCP2 foci exhibit liquid-like properties in vivo. Brero et al. showed
that MeCP2 forms round-shaped foci within the cell nucleus and foci in close proximity tend to fuse
over time. Furthermore, during mitosis, these chromatin clusters undergo fission and reform again after
cells have divided. MeCP2 was also shown to promote chromocenter clustering in a dose dependent
manner [174]. In addition, purified MeCP2 protein alone showed oblate ellipsoid appearance in
electron microscopy analysis [24]. Hence, and as depicted graphically in Figure 3, we propose that the
multivalent interactions with proteins and DNA/nucleosomes, together with its ability to oligomerize
and possibly create by itself phase separated compartments, altogether contribute to the in vivo ability
of MeCP2 to dynamically and efficiently cluster and compartmentalize heterochromatin.
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